A detailed history of Rhumbline Advisers transactions in Cassava Sciences Inc stock. As of the latest transaction made, Rhumbline Advisers holds 56,157 shares of SAVA stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,157
Previous 59,259 5.23%
Holding current value
$1.49 Million
Previous $731,000 125.99%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$9.57 - $35.08 $29,686 - $108,818
-3,102 Reduced 5.23%
56,157 $1.65 Million
Q2 2024

Aug 01, 2024

BUY
$12.35 - $26.11 $28,676 - $60,627
2,322 Added 4.08%
59,259 $731,000
Q1 2024

May 09, 2024

BUY
$18.44 - $26.41 $15,397 - $22,052
835 Added 1.49%
56,937 $1.16 Million
Q4 2023

Feb 08, 2024

SELL
$12.64 - $30.11 $8,178 - $19,481
-647 Reduced 1.14%
56,102 $1.26 Million
Q3 2023

Nov 09, 2023

SELL
$16.64 - $25.32 $4,193 - $6,380
-252 Reduced 0.44%
56,749 $944,000
Q2 2023

Aug 08, 2023

BUY
$21.59 - $27.88 $96,032 - $124,010
4,448 Added 8.46%
57,001 $1.4 Million
Q1 2023

May 11, 2023

BUY
$23.46 - $36.44 $18,322 - $28,459
781 Added 1.51%
52,553 $1.27 Million
Q4 2022

Feb 14, 2023

BUY
$27.82 - $44.16 $10,154 - $16,118
365 Added 0.71%
51,772 $1.53 Million
Q3 2022

Nov 10, 2022

BUY
$16.33 - $51.06 $75,526 - $236,152
4,625 Added 9.89%
51,407 $2.15 Million
Q2 2022

Aug 11, 2022

BUY
$17.22 - $38.47 $97,086 - $216,893
5,638 Added 13.7%
46,782 $1.32 Million
Q1 2022

May 12, 2022

BUY
$32.6 - $53.05 $72,698 - $118,301
2,230 Added 5.73%
41,144 $1.53 Million
Q4 2021

Feb 10, 2022

SELL
$36.77 - $90.91 $56,294 - $139,183
-1,531 Reduced 3.79%
38,914 $1.7 Million
Q3 2021

Nov 12, 2021

BUY
$41.79 - $135.3 $26,870 - $86,997
643 Added 1.62%
40,445 $2.51 Million
Q2 2021

Aug 05, 2021

SELL
$32.15 - $89.72 $181,197 - $505,661
-5,636 Reduced 12.4%
39,802 $3.4 Million
Q1 2021

May 06, 2021

BUY
$7.09 - $87.95 $81,166 - $1.01 Million
11,448 Added 33.68%
45,438 $2.04 Million
Q4 2020

Feb 10, 2021

BUY
$6.79 - $12.25 $74,988 - $135,289
11,044 Added 48.13%
33,990 $232,000
Q3 2020

Nov 12, 2020

BUY
$2.86 - $11.51 $2,639 - $10,623
923 Added 4.19%
22,946 $264,000
Q2 2020

Aug 13, 2020

BUY
$2.04 - $9.64 $44,926 - $212,301
22,023 New
22,023 $68,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.06B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.